Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1006 DFC · 1 trial · 1 indication
AUC (0-infinity) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for two formulations of MK-1006, FCT and DFC
Maximum plasma concentration for 2 formulations of MK-1006, FCT and DFC
| Arm | Type | Description |
|---|---|---|
| MK-1006 80 mg DFC | EXPERIMENTAL | Participants received a single dose of four 20 mg dry filled capsules of MK-1006 |
| MK-1006 80 mg FCT | EXPERIMENTAL | Participants received a single dose of two 40 mg film coated tablets of MK-1006 |
| Name | Type | Description |
|---|---|---|
| MK-1006 DFC | DRUG | Each dry filled capsule contains 20 mg MK-1006 |
| MK-1006 FCT | DRUG | Each film coated tablet contains 40 mg of MK-1006 |
Inclusion Criteria: * is a male or a female of non-child bearing potential * has type 2 diabetes (T2D) and is either being treated with diet and exercise alone or with a single or combination oral anti-hyperglycemic agent(s) * has been a nonsmoker for at least 6 months Exclusion Criteria: * has a...
Top 20 of 31 competitors
MK-1006 DFC is an investigational small molecule being developed for the treatment of Type 2 Diabetes. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in patients with Type 2 Diabetes to evaluate its pharmacokinetic profile.
MK-1006 DFC is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in patients with Type 2 Diabetes.
MK-1006 DFC is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development for Type 2 Diabetes.
MK-1006 DFC has one completed clinical trial, NCT00979459, titled 'A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)'. This Phase 1 study enrolled 12 participants with Type 2 Diabetes and was a controlled, randomized trial. The study is now completed.
MK-1006 DFC is a formulation of MK-1006. The clinical trial NCT00979459 evaluated the pharmacokinetics of two formulations of MK-1006, one of which is designated as MK-1006 DFC. The drug is being developed by Merck & Company for Type 2 Diabetes.